Vildagliptin is effective for glycemic control in diabetic patients undergoing either hemodialysis or peritoneal dialysis

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 321-329

  Ito, Hiroyuki ^a   Mifune, Mizuo ^a   Matsuyama, Eriko ^a   Furusho, Masahide ^a   Omoto, Takashi ^a   Shinozaki, Masahiro ^a   Nishio, Shinya ^a   Antoku, Shinichi ^a   Abe, Mariko ^a   Togane, Michiko ^a   Koga, Shoji ^a   Sanaka, Tsutomu ^a  

^a 2 24 18 Higashikoiwa   (Japan)

Author keywords

Diabetes; End stage kidney disease; Glycated albumin; Hemodialysis; Hemoglobin a1c; Peritoneal dialysis; Renal impairment; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

GLIMEPIRIDE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; MIGLITOL; VILDAGLIPTIN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84899083696     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0029-8     Document Type: Article

References (22)

1. Nakai S, Iseki K, Itami N, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial. 2012;16: 483-521.
2. Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24:909-13.
3. Hayashino Y, Fukuhara S, Akiba T, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia. 2007;50:1170-7.
4. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care. 2006;29: 1496-500.
5. Shima K, Komatsu M, Kawahara K, Minaguchi J, Kawashima S. Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis. Nephrology. 2010;15: 632-8.
6. Kawamura T, Umemura T, Hotta N. Cognitive impairment in diabetic patients: can diabetic control prevent cognitive decline? J Diabetes Invest. 2012;3:413-23.
7. Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:1894-900.
8. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13: 947-54.
9. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012;14:1032-9.
10. Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag. 2013;9:21-8.
11. Kume S, Uzu T, Takagi C, et al. Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis. J Diabetes Invest. 2012;3:298-301.
12. Ito M, Abe M, Okada K, et al. The Dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J. 2011;58: 979-87.
13. Terawaki Y, Nomiyama T, Akehi Y, et al. The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr. 2013;5:10.
14. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132-8.
15. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39:218-23.
16. Dejager S, Schweizer A, Foley JE. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag. 2012;8:339-48.
17. Kumeda Y, Inaba M, Shoji S, et al. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol. 2008;69:556-61.
18. Okada T, Nakao T, Matsumoto H, et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med. 2007;46:807-14.
19. Fukuoka K, Nakao K, Morimoto H, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology. 2008;13:278-83.
20. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73:1062-8.
21. Inaba M, Okuno S, Kumeda Y, Osaka CKD Expert Research, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18:896-903.
22. Freedman BI, Shenoy RN, Planer JA, et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritonealand hemodialysis. Perit Dial Int. 2010;30:72-9